News

X-GEN Pharmaceuticals is excited to announce we are evolving into a new company. Effective January 1, 2020, our new name is XGen Pharmaceuticals DJB, Inc. This change is not the result of a sale or merger of the company but simply a reflection of our growth in the changing pharmaceutical industry. Soon we will be [...]

Big Flats, NY., August 1st, 2019 – X-GEN Pharmaceuticals announced today the immediate availability in the United States of Dactinomycin for Injection, USP. Dactinomycin is an actinomycin indicated for the treatment of: • adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. • adult and pediatric patients with rhabdomyosarcoma, [...]

Big Flats, NY, March 1, 2017 – X-GEN Pharmaceuticals announced today it will begin marketing and distributing Piperacillin and Tazobactam for Injection. X-GEN’s Piperacillin and Tazobactam for Injection is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for the treatment of various bacterial infections. The medical community has been plagued by shortages and inconsistencies in [...]

Big Flats, NY, May 2, 2016 – X-GEN Pharmaceuticals and Exela Pharma Sciences announced today that Exela Pharma Sciences’ ANDA for Ibuprofen Lysine Injection was approved by the FDA. X-GEN’s Ibuprofen Lysine Injection, under licensing agreement with Exela, is therapeutically equivalent to Recordati Rare Diseases’ NeoProfen® Injection and is the first available generic alternative in [...]

Big Flats, NY, February 1, 2016 - X-GEN Pharmaceuticals, Inc. becomes the first generic alternative to receive FDA approval of their ANDA for the marketing and distribution of Lincomycin Injection, USP. Lincomycin is used to treat serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci when penicillin is inappropriate due to patient allergies [...]

Big Flats, NY, September 21, 2015 - X-GEN Pharmaceuticals, after recently receiving FDA approval of their ANDA, announced they are marketing and distributing Hydralazine Hydrochloride Injection, USP. Hydralazine is used to treat severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure. The industry [...]

Big Flats, NY, March 2, 2015 - X-GEN Pharmaceuticals announces availability of Magnesium Sulfate Injection, USP. Healthcare systems around the U.S are experiencing a shortage of Magnesium Sulfate, which is a critical component in Total Parenteral Nutrition (TPN), supplying vital nutrients to patients who need IV nutrition to stay alive. It also is indicated as [...]

Big Flats, NY, September 26, 2014 - X-GEN Pharmaceuticals, Inc. announced today that it is re-launching Nystatin Topical Powder USP, a generic product AT rated to Mycostatin®. Nystatin Topical Powder is an antibiotic used to treat skin infections caused by a wide variety of yeasts. X-GEN received FDA approval for Nystatin Topical in December of [...]

Big Flats, NY, May 19, 2014 — X-GEN Pharmaceuticals announced today it will begin marketing and distributing Polymyxin B for Injection, USP in a 10 pack carton. The new arrival is a product line extension to X-GEN’s current Polymyxin B drug, which is used to prevent infections that are strongly suspected or proven to be [...]

Big Flats, NY – (February 17, 2014) - X-GEN Pharmaceuticals announced today FDA approval to begin marketing and distributing Clonidine Hydrochloride Injection as part of a development and licensing agreement with Exela Pharma Sciences. Exela Pharma Sciences developed and is the commercial manufacturer of the drug product. Clonidine is AP rated to Duraclon® and is [...]